These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 1525190)

  • 41. Pharmacology and pharmacokinetics of 5-aminosalicylic acid.
    Klotz U; Maier KE
    Dig Dis Sci; 1987 Dec; 32(12 Suppl):46S-50S. PubMed ID: 3319458
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group.
    Hanauer S; Schwartz J; Robinson M; Roufail W; Arora S; Cello J; Safdi M
    Am J Gastroenterol; 1993 Aug; 88(8):1188-97. PubMed ID: 8338086
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis.
    Marshall JK; Irvine EJ
    Am J Gastroenterol; 2000 Jul; 95(7):1628-36. PubMed ID: 10925961
    [TBL] [Abstract][Full Text] [Related]  

  • 44. 5-amino salicylic acid absorption and metabolism in ulcerative colitis patients receiving maintenance sulphasalazine, olsalazine or mesalazine.
    Stretch GL; Campbell BJ; Dwarakanath AD; Yaqoob M; Stevenson A; Morris AI; Rhodes JM
    Aliment Pharmacol Ther; 1996 Dec; 10(6):941-7. PubMed ID: 8971292
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ulcerative colitis: responding to the challenges.
    Achkar JP
    Cleve Clin J Med; 2007 Sep; 74(9):657-60. PubMed ID: 17879519
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Conservative therapy of ulcerative colitis--long-term experience].
    Kölbel C; Goebell H
    Internist (Berl); 1991 Sep; 32(9):530-9. PubMed ID: 1683664
    [No Abstract]   [Full Text] [Related]  

  • 47. [Aminosalicylates in the treatment of chronic inflammatory bowel diseases].
    Hartmann F; Plauth M
    Internist (Berl); 1990 Nov; 31(11):702-6. PubMed ID: 2289856
    [No Abstract]   [Full Text] [Related]  

  • 48. Hypersensitivity to 5-aminosalicylic acid in patients with ulcerative colitis.
    Niv Y
    Isr J Med Sci; 1987 Nov; 23(11):1161-3. PubMed ID: 3436802
    [No Abstract]   [Full Text] [Related]  

  • 49. Topical treatment with 5-aminosalicylic in distal ulcerative colitis by using a new suppository preparation. A double-blind placebo controlled trial.
    Campieri M; Gionchetti P; Belluzzi A; Brignola C; Tampieri M; Iannone P; Brunetti G; Miglioli M; Barbara L
    Int J Colorectal Dis; 1990 May; 5(2):79-81. PubMed ID: 2193075
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis.
    Riley SA; Mani V; Goodman MJ; Herd ME; Dutt S; Turnberg LA
    Gastroenterology; 1988 Jun; 94(6):1383-9. PubMed ID: 2896139
    [TBL] [Abstract][Full Text] [Related]  

  • 51. 5-ASA enema therapy.
    Hanauer SB
    Neth J Med; 1989 Jun; 35 Suppl 1():S11-20. PubMed ID: 2702307
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The efficacy of oral 5-ASAs in the treatment of active ulcerative colitis: a systematic review.
    Kane SV; Bjorkman DJ
    Rev Gastroenterol Disord; 2003; 3(4):210-8. PubMed ID: 14668693
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Active moiety of sulfasalazine.
    Greenwell BE
    Dig Dis Sci; 1989 Nov; 34(11):1804-5. PubMed ID: 2573487
    [No Abstract]   [Full Text] [Related]  

  • 54. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.
    Rachmilewitz D
    BMJ; 1989 Jan; 298(6666):82-6. PubMed ID: 2563951
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Nephrotic syndrome from 5-ASA for ulcerative colitis? Complicated by carcinoma of the colon and sclerosing cholangitis.
    Fornaciari G; Maccari S; Borgatti PP; Rustichelli R; Amelio N; Lattuada I; Plancher AC
    J Clin Gastroenterol; 1997 Jan; 24(1):37-9. PubMed ID: 9013349
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis.
    Levine DS; Riff DS; Pruitt R; Wruble L; Koval G; Sales D; Bell JK; Johnson LK
    Am J Gastroenterol; 2002 Jun; 97(6):1398-407. PubMed ID: 12094857
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The effect of mesalamine and nicotine in the treatment of inflammatory bowel disease.
    Bonapace CR; Mays DA
    Ann Pharmacother; 1997; 31(7-8):907-13. PubMed ID: 9220055
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A dynamic model of colonic concentrations of delayed-release 5-aminosalicylic acid (Asacol).
    Thorpe MP; Ehrenpreis ED; Putt KS; Hannon B
    Aliment Pharmacol Ther; 2009 Jun; 29(11):1193-201. PubMed ID: 19222409
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Therapeutic efficacy of 5-ASA molecules in idiopathic intestinal inflammatory diseases: critical review].
    Van Gossum A
    Acta Gastroenterol Belg; 1992; 55(5-6):462-71. PubMed ID: 1363167
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Experience with Eudragit-S coated mesalamine (Asacol) in inflammatory bowel disease: adverse events.
    Nichols TW
    J Clin Gastroenterol; 1994 Mar; 18(2):181. PubMed ID: 8189029
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.